Hanshow Technology
301275
Yong Jie New Material
603271
ZZT
873726
UESTCOC
920008
Geovis Insighter Technology
920116
CN Stock MarketDetailed Quotes
688321 Shenzhen Chipscreen Biosciences
- 18.88
- -0.29-1.51%
Noon Break Mar 11 11:29 CST
7.70BMarket Cap-109.77P/E (TTM)
19.30High18.86Low36.97KlotVolume18.95Open19.17Pre Close70.51MTurnover0.91%Turnover Ratio86.61P/E (Static)407.80MShares25.9952wk High5.07P/B7.70BFloat Cap15.1552wk Low23.00Limit Up407.80MShs Float125.00Historical High15.34Limit Down2.30%Amplitude12.47Historical Low--Dividend TTM19.07Avg Price19.31KlotAsk--Div YieldTTM100Lot Size16.66KlotBid
Shenzhen Chipscreen Biosciences News
Notice on receipt of the “Notice of Acceptance of the Request for Invalidity Declaration”
Microchip Biotech: Announcement on Appointment of Co-General Manager
Microchip Biotech: Announcement on the extension of some fund-raising investment projects
Announcement on the extension of some fund-raising investment projects
Notice on receipt of the “Notice of Acceptance of the Request for Invalidity Declaration”
Shenzhen Microchip Biotechnology Co., Ltd. Internal Reporting System for Important Matters (January 2025)
Announcement on the appointment of a co-general manager
Announcement on the results of convertible debt-to-equity swaps and changes in shares
Announcement of Resolutions of the 2024 Second Extraordinary General Meeting of Shareholders
Legal Opinion of Shanghai Tongli Law Firm on the 2024 Second Extraordinary General Meeting of Shareholders of Shenzhen Microchip Biotechnology Co., Ltd.
Announcement on the results of the phase III clinical trial of Theoroni monotherapy for third-line small cell lung cancer and above
Voluntary disclosure of the announcement on the inclusion of the company\'s products in the national medical insurance catalogue
2024 Second Extraordinary General Meeting of Shareholders Meeting Materials
Voluntary Disclosure Notice Regarding Acceptance of Cedarbonamide Clinical Trial Applications
Notice on Convening the Second Extraordinary General Meeting of Shareholders in 2024
Shenzhen Microchip Biotechnology Co., Ltd. shareholder return plan for the next three years (2024-2026)
Notice on Risk Alerts for Issuing A-Shares to Specific Targets with Diluted Spot Returns in 2024 and the Company\'s Adoption of Corrective Measures and Related Entities\' Commitments
Announcement on early termination of promotion cooperation with Haizheng Pharmaceutical
Announcement on not revising the conversion price of “Microchip Bonds” downwards
Voluntary disclosure announcement on acceptance of the CS231295 tablet clinical trial application
